Drug Profile
NGD 961
Alternative Names: NGD 96-1; NGD 9611Latest Information Update: 11 Jan 2001
Price :
$50
*
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; Pfizer
- Class Anxiolytics; Hypnosedatives
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 11 Jan 2001 Discontinued-I for Insomnia in USA (Unknown route)
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 05 Feb 1999 Phase-I clinical trials for Insomnia in USA (Unknown route)